The guidelines development group for updating the WHO classification of hyperglycaemia and the diagnostic criteria for intermediate hyperglycaemia
WHO has previously published three technical reports and two guidelines on diagnosis and classification of diabetes (WHO 1965, WHO 1980, WHO 1985, WHO 1999, WHO/IDF 2006). In 2006 WHO, updated the section on definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia, but not the section on classification. The objectives of the guidelines are:
- To determine whether a revision and/or refinement of the 1999 classification of hyperglycaemia is warranted based on new available evidence, and if necessary, to revise and/or refine the existing classification.
- To review the current (2006) diagnostic cut-off levels for of plasma glucose and HbA1C for the diagnosis of intermediate hyperglycaemia. The revision will be based on:
- The relationship between existing various plasma glucose and HbA1c cut-off values and the risk of developing diabetes, microvascular complications, CVD, as well as the risk of dying.
- The effect of interventions (lifestyle, medication) on incidence of diabetes, microvascular complications, CVD, CVD mortality and all-cause mortality in people with intermediate hyperglycaemia as defined by the various cut-off values for plasma glucose and HbA1c.
The 2013 guidelines on the Classification and diagnosis of hyperglycaemia first detected in pregnancy will not be updated for this guideline.
In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/ normative advice, the names and brief biographies of individuals (“Published Information”) being considered for participation in a WHO-convened Guideline Development Group are disclosed for public notice and comment.
The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.
The comments received by WHO through the public notice and comment process are treated confidentially and receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO’s conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.
Guideline Development Groups provide technical and/or normative advice and recommendations to WHO. Participation in a Guideline Development Group convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO.
The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interest, will be reported publically in accordance with WHO policies.